<DOC>
	<DOCNO>NCT00000760</DOCNO>
	<brief_summary>To study anti-HIV activity various dos Ro 24-7429 monotherapy base virologic immunologic endpoint . To study safety tolerance Ro 24-7429 . To explore relationship exposure Ro 24-7429 metabolite antiviral activity drug toxicity . To determine safe , tolerable , active dose regimen Ro 24-7429 , make preliminary observation Ro 24-7429 combination another antiretroviral nucleoside . The HIV genome contains number gene regulate viral replication . Control activity gene encode protein represent potential target development new antiretroviral drug . The tat ( transactivator transcription HIV ) antagonist Ro 24-7429 first compound clinical testing utilizes approach therapy HIV infection .</brief_summary>
	<brief_title>A Randomized Study Activity , Safety , Tolerance Oral Ro 24-7429 ( Tat Antagonist ) Patients With HIV Infection</brief_title>
	<detailed_description>The HIV genome contains number gene regulate viral replication . Control activity gene encode protein represent potential target development new antiretroviral drug . The tat ( transactivator transcription HIV ) antagonist Ro 24-7429 first compound clinical testing utilizes approach therapy HIV infection . Ninety-six patient ( four treatment arm 24 patient ) randomize receive oral Ro 24-7429 1 3 dos nucleoside control ( either zidovudine didanosine ) . The study blind arm receive Ro 24-7429 . Treatment continue 12 week . After 12 week , patient nucleoside control arm receive high tolerate dose Ro 24-7429 addition nucleoside .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis P. carinii pneumonia , TB , mucocutaneous candidiasis . Methadone maintenance . Hormonal contraceptive . Patients must : HIV1 seropositivity . CD4 count 50 500 cells/mm3 . Life expectancy least 24 week . Stable weight ( +/ 2 kg ) 28 day prior study entry ( history ) . NOTE : At least 50 percent patient must p24 antigen positive ( &gt; = 50 pg/ml ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known suspected hypersensitivity benzodiazepine . Presence malignancy basal cell carcinoma limit cutaneous Kaposi 's sarcoma ( defined five lesion mucosal involvement ) . Ongoing diarrhea , define 2 liquid stool per day . History , physical exam , laboratory result consistent subclinical AIDSdefining opportunistic infection . Grade 2 great sign symptom AIDS Dementia Complex . Evidence clinically significant cardiac , respiratory , hepatic , gastrointestinal , endocrine , hematologic , psychiatric , neurologic , dermatologic , allergic disease . Concurrent Medication : Excluded : Chronic suppressive therapy CMV , MAI , toxoplasmosis , cryptococcosis , cryptosporidiosis , coccidioidomycosis , histoplasmosis . ddC , ddI , AZT ( except control group ) experimental antiretrovirals immunomodulating agent . Other medication exclude study . Patients follow prior condition exclude : History serious adverse reaction benzodiazepine . History intolerance AZT 600 mg/day less ddI 400 mg/day less . History unexplained fever , define temperature 38.5 deg C great without night sweat 7 past 28 day . Prior Medication : Excluded : Benzodiazepines within 14 day prior study entry . Active drug alcohol abuse would interfere study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Gene Products , tat</keyword>
</DOC>